A FDA advisory panel voted overwhelmingly against a polarizing potential treatment for ALS, concluding that supporting data were inadequate. Read this story
A FDA advisory panel voted overwhelmingly against a polarizing potential treatment for ALS, concluding that supporting data were inadequate. Read this story
More from STAT | Pharma Pharmalot pharmalittle STAT+